173 related articles for article (PubMed ID: 22010015)
1. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
Soria JC; Márk Z; Zatloukal P; Szima B; Albert I; Juhász E; Pujol JL; Kozielski J; Baker N; Smethurst D; Hei YJ; Ashkenazi A; Stern H; Amler L; Pan Y; Blackhall F
J Clin Oncol; 2011 Nov; 29(33):4442-51. PubMed ID: 22010015
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
Ramalingam SS; Maitland ML; Frankel P; Argiris AE; Koczywas M; Gitlitz B; Thomas S; Espinoza-Delgado I; Vokes EE; Gandara DR; Belani CP
J Clin Oncol; 2010 Jan; 28(1):56-62. PubMed ID: 19933908
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
Geng C; Hou J; Zhao Y; Ke X; Wang Z; Qiu L; Xi H; Wang F; Wei N; Liu Y; Yang S; Wei P; Zheng X; Huang Z; Zhu B; Chen WM
Am J Hematol; 2014 Nov; 89(11):1037-42. PubMed ID: 25092564
[TBL] [Abstract][Full Text] [Related]
4. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Wainberg ZA; Messersmith WA; Peddi PF; Kapp AV; Ashkenazi A; Royer-Joo S; Portera CC; Kozloff MF
Clin Colorectal Cancer; 2013 Dec; 12(4):248-54. PubMed ID: 24075777
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
Ouyang X; Shi M; Jie F; Bai Y; Shen P; Yu Z; Wang X; Huang C; Tao M; Wang Z; Xie C; Wu Q; Shu Y; Han B; Zhang F; Zhang Y; Hu C; Ma X; Liang Y; Wang A; Lu B; Shi Y; Chen J; Zhuang Z; Wang J; Huang J; Wang C; Bai C; Zhou X; Li Q; Chen F; Yu H; Feng J
Invest New Drugs; 2018 Apr; 36(2):315-322. PubMed ID: 29134432
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
von Pawel J; Harvey JH; Spigel DR; Dediu M; Reck M; Cebotaru CL; Humphreys RC; Gribbin MJ; Fox NL; Camidge DR
Clin Lung Cancer; 2014 May; 15(3):188-196.e2. PubMed ID: 24560012
[TBL] [Abstract][Full Text] [Related]
7. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells.
Trivedi R; Mishra DP
Front Oncol; 2015; 5():69. PubMed ID: 25883904
[TBL] [Abstract][Full Text] [Related]
8. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Forero-Torres A; Infante JR; Waterhouse D; Wong L; Vickers S; Arrowsmith E; He AR; Hart L; Trent D; Wade J; Jin X; Wang Q; Austin T; Rosen M; Beckman R; von Roemeling R; Greenberg J; Saleh M
Cancer Med; 2013 Dec; 2(6):925-32. PubMed ID: 24403266
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Cohn AL; Tabernero J; Maurel J; Nowara E; Sastre J; Chuah BYS; Kopp MV; Sakaeva DD; Mitchell EP; Dubey S; Suzuki S; Hei YJ; Galimi F; McCaffery I; Pan Y; Loberg R; Cottrell S; Choo SP
Ann Oncol; 2013 Jul; 24(7):1777-1785. PubMed ID: 23510984
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Shaw AT; Kim DW; Nakagawa K; Seto T; Crinó L; Ahn MJ; De Pas T; Besse B; Solomon BJ; Blackhall F; Wu YL; Thomas M; O'Byrne KJ; Moro-Sibilot D; Camidge DR; Mok T; Hirsh V; Riely GJ; Iyer S; Tassell V; Polli A; Wilner KD; Jänne PA
N Engl J Med; 2013 Jun; 368(25):2385-94. PubMed ID: 23724913
[TBL] [Abstract][Full Text] [Related]
12. Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells.
De Miguel D; Gallego-Lleyda A; Anel A; Martinez-Lostao L
Leuk Res; 2015 Jun; 39(6):657-66. PubMed ID: 25882551
[TBL] [Abstract][Full Text] [Related]
13. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis.
von Karstedt S; Conti A; Nobis M; Montinaro A; Hartwig T; Lemke J; Legler K; Annewanter F; Campbell AD; Taraborrelli L; Grosse-Wilde A; Coy JF; El-Bahrawy MA; Bergmann F; Koschny R; Werner J; Ganten TM; Schweiger T; Hoetzenecker K; Kenessey I; Hegedüs B; Bergmann M; Hauser C; Egberts JH; Becker T; Röcken C; Kalthoff H; Trauzold A; Anderson KI; Sansom OJ; Walczak H
Cancer Cell; 2015 Apr; 27(4):561-73. PubMed ID: 25843002
[TBL] [Abstract][Full Text] [Related]
14. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Fuchs CS; Fakih M; Schwartzberg L; Cohn AL; Yee L; Dreisbach L; Kozloff MF; Hei YJ; Galimi F; Pan Y; Haddad V; Hsu CP; Sabin A; Saltz L
Cancer; 2013 Dec; 119(24):4290-8. PubMed ID: 24122767
[TBL] [Abstract][Full Text] [Related]
15. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Lee SM; Khan I; Upadhyay S; Lewanski C; Falk S; Skailes G; Marshall E; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Chao D; Middleton G; Bulley S; Ngai Y; Rudd R; Hackshaw A; Boshoff C
Lancet Oncol; 2012 Nov; 13(11):1161-70. PubMed ID: 23078958
[TBL] [Abstract][Full Text] [Related]
16. Getting TRAIL back on track for cancer therapy.
Lemke J; von Karstedt S; Zinngrebe J; Walczak H
Cell Death Differ; 2014 Sep; 21(9):1350-64. PubMed ID: 24948009
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells.
De Miguel D; Gallego-Lleyda A; Galan-Malo P; Rodriguez-Vigil C; Marzo I; Anel A; Martinez-Lostao L
Clin Transl Oncol; 2015 Aug; 17(8):657-67. PubMed ID: 25967100
[TBL] [Abstract][Full Text] [Related]
18. A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death.
Bucur O; Gaidos G; Yatawara A; Pennarun B; Rupasinghe C; Roux J; Andrei S; Guo B; Panaitiu A; Pellegrini M; Mierke DF; Khosravi-Far R
Sci Rep; 2015 May; 5():9893. PubMed ID: 25962125
[TBL] [Abstract][Full Text] [Related]
19. Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.
Nair PM; Flores H; Gogineni A; Marsters S; Lawrence DA; Kelley RF; Ngu H; Sagolla M; Komuves L; Bourgon R; Settleman J; Ashkenazi A
Proc Natl Acad Sci U S A; 2015 May; 112(18):5679-84. PubMed ID: 25902490
[TBL] [Abstract][Full Text] [Related]
20. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis.
Lu M; Lawrence DA; Marsters S; Acosta-Alvear D; Kimmig P; Mendez AS; Paton AW; Paton JC; Walter P; Ashkenazi A
Science; 2014 Jul; 345(6192):98-101. PubMed ID: 24994655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]